The standard of care is evolving to recognize that both anatomical and functional information are crucial in determining whether a patient has myocardial ischemia, yet the available tools cause physician's to choose between efficiency and efficacy. This information is important in diagnosing ischemic heart disease (IHD), but it is especially crucial in recognizing disease that our current modalities are not built to capture. The majority of patients assessed for angina have no angiographic abnormalities, but still have symptoms of a coronary disorder. It is estimated that 50-65% of these patients have coronary microvascular dysfunction (CMD). CardioFlux is a ground-breaking tool that gives us that functional information, including the recognition of CMD, through a non-invasive 90-second scan with zero radiation exposure to the patient. With proven accuracy, CardioFlux is a true disruptor aiming to lower the cost of care with high-tech advanced imaging diagnosing IHD, with a better experience for patients and providers.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
